drugset / Trial / NCT04543890
A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC
Phase 2
Unknown
300 enrolled
Zhejiang Cancer Hospital
Chinese PLA General Hospital · collabFirst Affiliated Hospital, Sun Yat-Sen University · collabGuangdong Medical College · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
For most of the patients with limited-stage SCLC, thoracic radiotherapy combined with chemotherapy is the standard treatment at present. However, the optimal dose / fraction of thoracic radiotherapy for limited-stage SCLC is still in controversial.This study is designed as a prospecitive randomized non-inferiority trial.
Timeline
- Start
- 2018-05-01
- Primary completion
- 2023-06-01
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |